[go: up one dir, main page]

MX2016006277A - Secuencia de endolisina kz144 modificada. - Google Patents

Secuencia de endolisina kz144 modificada.

Info

Publication number
MX2016006277A
MX2016006277A MX2016006277A MX2016006277A MX2016006277A MX 2016006277 A MX2016006277 A MX 2016006277A MX 2016006277 A MX2016006277 A MX 2016006277A MX 2016006277 A MX2016006277 A MX 2016006277A MX 2016006277 A MX2016006277 A MX 2016006277A
Authority
MX
Mexico
Prior art keywords
polypeptides
present
nucleic acids
relates
sequence
Prior art date
Application number
MX2016006277A
Other languages
English (en)
Other versions
MX374403B (es
Inventor
Miller Stefan
Sterner Reinhard
Stüer Heike
Original Assignee
Lysando Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lysando Ag filed Critical Lysando Ag
Publication of MX2016006277A publication Critical patent/MX2016006277A/es
Publication of MX374403B publication Critical patent/MX374403B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a polipéptidos que comprenden una secuencia de aminoácidos que presenta una identidad de secuencia de al menos aproximadamente un 90 % con la secuencia de SEQ ID NO: 1. Dichos polipéptidos degradan preferentemente al peptidoglucano de bacterias Gram-negativas, en particular, de bacterias Pseudomonas y/o Campylobacter. Además, la presente invención se refiere a ácidos nucleicos que codifican dichos polipéptidos, a vectores que comprenden dichos ácidos nucleicos y a las correspondientes células hospedadoras. Finalmente, la presente invención se refiere a composiciones que comprenden dichos polipéptidos, ácidos nucleicos, vectores y/o células hospedadoras de acuerdo con la presente invención.
MX2016006277A 2013-11-14 2014-11-14 Secuencia de endolisina kz144 modificada. MX374403B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2013/073869 WO2015070911A1 (en) 2013-11-14 2013-11-14 Modified kz144 endolysin sequence
PCT/EP2014/074671 WO2015071436A1 (en) 2013-11-14 2014-11-14 Modified kz144 endolysin sequence

Publications (2)

Publication Number Publication Date
MX2016006277A true MX2016006277A (es) 2017-01-05
MX374403B MX374403B (es) 2025-03-06

Family

ID=49582760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006277A MX374403B (es) 2013-11-14 2014-11-14 Secuencia de endolisina kz144 modificada.

Country Status (10)

Country Link
US (1) US10184120B2 (es)
JP (1) JP6745720B2 (es)
KR (1) KR102302044B1 (es)
CN (1) CN105793419B (es)
AU (1) AU2014350104B2 (es)
BR (1) BR112016011091B1 (es)
CA (1) CA2929686C (es)
EA (1) EA035959B1 (es)
MX (1) MX374403B (es)
WO (2) WO2015070911A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018003101A (es) 2015-09-17 2018-12-17 Contrafect Corp Activo de polipeptidos de lisina contra bacterias gram-negativas.
US20190125897A1 (en) * 2016-04-28 2019-05-02 Lysando Ag Antimicrobial agents against salmonella bacteria
WO2017203471A1 (en) * 2016-05-27 2017-11-30 Sasinapas Co., Ltd. Endolysin variant
WO2018100408A1 (en) * 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
KR20200012844A (ko) * 2017-04-03 2020-02-05 사시나파스 컴퍼니 리미티드 조작된 그람-음성 엔도리신
CN112204054A (zh) * 2018-05-30 2021-01-08 莱桑多公司 新抗微生物融合蛋白
CN111304181B (zh) * 2020-02-17 2021-11-23 华东理工大学 一种基因工程改造后的副溶血性弧菌噬菌体裂解酶及其制备方法和应用
KR20250044545A (ko) 2023-09-23 2025-04-01 조배근 사료급이기 청소기

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289092C (en) * 1987-01-15 1991-09-17 Robert A. Hallewell Thermostable human cu/zn superoxide dismutase muteins
EP0285123A3 (en) 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
ZA936811B (en) * 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
JPH08127540A (ja) * 1994-09-09 1996-05-21 Takeda Chem Ind Ltd 抗潰瘍医薬
JP2010536354A (ja) * 2007-08-22 2010-12-02 ヒグロス インベスト ゲーエムベーハー ヒトおよび動物のブドウ球菌(Staphylococcus)感染症において使用するための新しいタンパク質
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
SI2445515T1 (sl) * 2009-06-26 2016-08-31 Lysando Ag Antimikrobna sredstva
CN102482655B (zh) 2009-06-26 2018-04-10 莱桑多公司 抗微生物剂
US8846865B2 (en) * 2009-08-24 2014-09-30 Lysando Ag Endolysin OBPgpLYS
CN103119158B (zh) * 2010-04-27 2015-04-08 莱桑多公司 减少生物膜的方法
GB201018518D0 (en) * 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
KR20130142837A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 슈도모나스 에루기노사의 박테리오파아지 및 그 용도

Also Published As

Publication number Publication date
EA035959B1 (ru) 2020-09-07
WO2015071436A1 (en) 2015-05-21
NZ719338A (en) 2022-03-25
CA2929686A1 (en) 2015-05-21
AU2014350104A1 (en) 2016-05-12
EA201691004A1 (ru) 2017-01-30
JP2016537979A (ja) 2016-12-08
KR20160085342A (ko) 2016-07-15
CA2929686C (en) 2023-08-08
MX374403B (es) 2025-03-06
AU2014350104B2 (en) 2020-03-05
WO2015070911A1 (en) 2015-05-21
US20160281074A1 (en) 2016-09-29
US10184120B2 (en) 2019-01-22
BR112016011091A2 (pt) 2017-12-05
CN105793419A (zh) 2016-07-20
KR102302044B1 (ko) 2021-09-15
BR112016011091B1 (pt) 2024-02-06
JP6745720B2 (ja) 2020-08-26
CN105793419B (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
MX2016006277A (es) Secuencia de endolisina kz144 modificada.
EA201990860A1 (ru) Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
MX387336B (es) Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
MX383537B (es) Mutantes de proteína f de rsv.
WO2014202616A3 (en) Rasamsonia gene and use thereof
EA201401211A1 (ru) Улучшенные варианты фермента химозина
MX2023001119A (es) Variantes de enzimas y polinucleotidos que las codifican.
PH12014501726A1 (en) Glyphosate resistant plants and associated methods
MX2021010668A (es) Proteinas de fusion de citoquinas.
BR112017020308A2 (pt) udp-glicosiltransferases
MX382218B (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2014202622A3 (en) Rasamsonia gene and use thereof
EP3760713A3 (en) Lipase variants and polynucleotides encoding same
MX388191B (es) Polinucleótido optimizado por codones para la expresión de alto nivel de crm197.
MX2015015274A (es) Ruta de ácido organico novedosa.
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
MX2016003405A (es) Hetero-transglicosilasa novedosa y usos de la misma.
BR112012033396A2 (pt) Polipetídeo tendo atividade swollenin e seus usos.
AR101146A1 (es) Proteína con actividad xilanasa
BR112018000849A2 (pt) ?composições, organismos, sistemas e métodos de cítricos resistentes a patógeno?
WO2014202623A3 (en) Rasamsonia gene and use thereof
AR102120A1 (es) Interferón modificado con inmunogenicidad reducida

Legal Events

Date Code Title Description
FG Grant or registration